サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1646705

関節リウマチ診断テストの世界市場

Rheumatoid Arthritis Diagnosis Tests

出版日
ページ情報
英文 441 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
関節リウマチ診断テストの世界市場
出版日: 2025年01月31日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 441 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

関節リウマチ診断テストの世界市場は2030年までに10億米ドルに達する見込み

2023年に6億9,110万米ドルと推定される関節リウマチ診断テストの世界市場は、分析期間2023-2030年にCAGR 5.7%で成長し、2030年には10億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである血清学検査は、CAGR 6.1％を記録し、分析期間終了時には7億2,360万米ドルに達すると予測されます。RA治療効率モニタリング検査分野の成長率は、分析期間中CAGR 4.9％と推定されます。

米国市場は1億8,140万米ドルと推定、中国はCAGR 7.4％で成長予測

米国の関節リウマチ診断テスト市場は、2023年に1億8,140万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億7,080万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは7.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.2%と5.1%と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界の関節リウマチ診断テスト市場- 主要動向と促進要因まとめ

関節リウマチ診断テストとは何か、なぜ必要なのか？

関節リウマチ（RA）診断検査は、世界中で数百万人が罹患しているこの慢性的な自己免疫疾患を特定し、管理するための重要なツールです。これらの検査の主な目的は、バイオマーカー、炎症マーカー、およびRAに関連する症状を早期に検出し、タイムリーな治療と患者の転帰の改善を可能にすることです。一般的な診断アプローチには、リウマトイド因子（RF）検査、抗環状シトルリン化ペプチド（抗CCP）抗体検査、赤血球沈降速度（ESR）検査、C反応性蛋白（CRP）検査などの血液検査や、X線検査、MRI検査、超音波検査などの画像検査があります。これらの検査はRAを確認するだけでなく、他の自己免疫疾患や筋骨格系疾患との鑑別にも役立ちます。患者教育キャンペーンや医師のイニシアチブにより、早期診断に対する認識が高まり、RA診断ツールの採用が世界中で広がっています。

技術革新は診断の精度とアクセシビリティをどのように変えているか？

RA診断の分野では、特に精密診断法の開発において大きな進歩が見られます。新世代のバイオマーカーベースのアッセイや遺伝子検査は、比類ない精度を提供し、以前の方法を悩ませていた偽陰性や偽陽性を減少させています。ポイントオブケア診断キットやポータブル機器は、遠隔地や十分なサービスを受けていない地域でのRA検査を可能にし、アクセシビリティに革命をもたらしています。デジタル画像やAIを活用した診断ツールは、複雑なスキャンの解釈を合理化し、データに裏打ちされた洞察をリアルタイムで医師に提供しています。さらに、現在進行中の分子診断学の研究は、病気の進行を予測し、治療計画をカスタマイズすることを可能にする予測分析への道を開いています。これらの進歩は診断精度を向上させるだけでなく、RA診断にかかる時間とコストを削減しています。

地域間でRA診断検査の需要が伸びている理由は？

RA診断検査に対する需要は、特に高齢化社会における有病率の上昇に後押しされ、世界的に拡大しています。北米や欧州を含む新興国市場では、ヘルスケアインフラ、保険、医師の意識が向上しているため、高い普及率を示しています。逆に、アジア太平洋やラテンアメリカの新興国は、診断施設へのアクセスの改善や政府主導の医療改革により、急速な成長を遂げています。さらに、ライフスタイルに関連した炎症性疾患の負担が増加していることに加え、自己免疫疾患管理への注目が高まっていることも、包括的な診断ソリューションの必要性を高めています。公衆衛生キャンペーンや診断会社とヘルスケアプロバイダーとの協力関係も、RA診断ツールの普及に重要な役割を果たしています。

何がRA診断市場の成長を牽引しているのか？

関節リウマチ診断市場の成長は、診断ツールの技術的進歩、疾患の早期発見への注目の高まり、患者の意識の高まりなど、いくつかの要因によって牽引されています。新規バイオマーカーに基づく検査の開発、画像診断のためのAIや機械学習の進歩は、検査の精度と効率を高めています。個別化医療が重視されるようになり、RAに対する遺伝子検査や分子検査の導入が促進されています。さらに、RAおよび関連する自己免疫疾患の罹患率の増加と、新興市場におけるヘルスケアへのアクセスの向上が、需要を大幅に押し上げています。意識の高まりや積極的な健康管理動向の影響を受けた消費者行動も、診断検査の利用拡大に寄与しています。診断薬企業とヘルスケアプロバイダーとの戦略的パートナーシップや政府の支援策が、市場の成長軌道をさらに後押ししています。

セグメント

検査タイプ（血清学検査、RA治療効率モニタリング検査）、エンドユース（診断ラボエンドユース、病院エンドユース、外来手術センターエンドユース）

調査対象企業の例（注目の66社）

  • Abbott Core Laboratory
  • Augurex Life Sciences Corp.
  • Beckman Coulter, Inc.
  • Bio Rad Laboratories Inc.
  • Exagen Inc.
  • imaware, Inc.
  • Qiagen NV
  • Roche Diagnostics International AG
  • Siemens Healthcare Private Limited
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP14459

Global Rheumatoid Arthritis Diagnosis Tests Market to Reach US$1.0 Billion by 2030

The global market for Rheumatoid Arthritis Diagnosis Tests estimated at US$691.1 Million in the year 2023, is expected to reach US$1.0 Billion by 2030, growing at a CAGR of 5.7% over the analysis period 2023-2030. Serology Tests, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$723.6 Million by the end of the analysis period. Growth in the Monitoring RA Treatment Efficiency Tests segment is estimated at 4.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$181.4 Million While China is Forecast to Grow at 7.4% CAGR

The Rheumatoid Arthritis Diagnosis Tests market in the U.S. is estimated at US$181.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$170.8 Million by the year 2030 trailing a CAGR of 7.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.2% and 5.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Rheumatoid Arthritis Diagnosis Tests Market - Key Trends & Drivers Summarized

What Are Rheumatoid Arthritis Diagnosis Tests and Why Are They Essential?

Rheumatoid arthritis (RA) diagnosis tests are critical tools in identifying and managing this chronic autoimmune disorder that affects millions globally. The primary aim of these tests is to detect biomarkers, inflammatory markers, and symptoms associated with RA at an early stage, enabling timely treatment and improved patient outcomes. Common diagnostic approaches include blood tests such as the rheumatoid factor (RF) test, anti-cyclic citrullinated peptide (anti-CCP) antibody test, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) test, alongside imaging techniques like X-rays, MRIs, and ultrasounds. These tests not only confirm RA but also help differentiate it from other autoimmune or musculoskeletal disorders. Increasing awareness about early diagnosis, driven by patient education campaigns and physician initiatives, is broadening the adoption of RA diagnostic tools worldwide.

How Are Innovations Transforming Diagnostic Accuracy and Accessibility?

The field of RA diagnosis has witnessed significant advancements, particularly in the development of precision diagnostics. New-generation biomarker-based assays and genetic tests are offering unparalleled accuracy, reducing false negatives or positives that plagued earlier methods. Point-of-care diagnostic kits and portable devices are revolutionizing accessibility, allowing for RA testing in remote or underserved areas. Digital imaging and AI-driven diagnostic tools are streamlining the interpretation of complex scans, providing physicians with real-time, data-backed insights. Furthermore, ongoing research in molecular diagnostics is paving the way for predictive analytics, enabling healthcare providers to forecast disease progression and customize treatment plans. These advancements are not only enhancing diagnostic precision but are also reducing the time and cost associated with RA identification.

Why Is the Demand for RA Diagnosis Tests Growing Across Geographies?

Demand for RA diagnostic tests is escalating globally, fueled by the rising prevalence of the disease, particularly among aging populations. Developed markets, including North America and Europe, are experiencing high adoption rates owing to better healthcare infrastructure, insurance coverage, and physician awareness. Conversely, emerging economies in Asia-Pacific and Latin America are witnessing rapid growth due to improving access to diagnostic facilities and government-led healthcare reforms. Additionally, the increasing burden of lifestyle-related inflammatory conditions, coupled with the growing focus on autoimmune disease management, is intensifying the need for comprehensive diagnostic solutions. Public health campaigns and collaborations between diagnostic companies and healthcare providers are also playing a pivotal role in expanding the reach of RA diagnosis tools.

What Is Driving the Growth in the RA Diagnosis Market?

The growth in the rheumatoid arthritis diagnosis market is driven by several factors, including technological advancements in diagnostic tools, increased focus on early disease detection, and rising patient awareness. The development of novel biomarker-based tests, along with advancements in AI and machine learning for imaging diagnostics, is enhancing test accuracy and efficiency. A growing emphasis on personalized medicine is encouraging the adoption of genetic and molecular testing for RA. Furthermore, the increasing incidence of RA and related autoimmune disorders, coupled with improved healthcare accessibility in emerging markets, is significantly boosting demand. Consumer behavior, influenced by heightened awareness and proactive health management trends, is also contributing to the expanding use of diagnostic tests. Strategic partnerships between diagnostic companies and healthcare providers, as well as supportive government initiatives, are further propelling the market’s growth trajectory.

SCOPE OF STUDY:

The report analyzes the Rheumatoid Arthritis Diagnosis Tests market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Serology Tests, Monitoring RA Treatment Efficiency Tests); End-Use (Diagnostic Laboratories End-use, Hospitals End-use, Ambulatory Surgical Centers End-use)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 66 Featured) -

  • Abbott Core Laboratory
  • Augurex Life Sciences Corp.
  • Beckman Coulter, Inc.
  • Bio Rad Laboratories Inc.
  • Exagen Inc.
  • imaware, Inc.
  • Qiagen NV
  • Roche Diagnostics International AG
  • Siemens Healthcare Private Limited
  • Svar Life Science AB
  • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • A Prelude to Rheumatoid Arthritis
    • Diagnostic Tests of Rheumatoid Arthritis
    • Competition
    • EXHIBIT 1: Rheumatoid Arthritis Diagnosis Tests - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Economic Frontiers: Trends, Trials & Transformations
    • EXHIBIT 2: In a World Torn by Geopolitical Instability & War, Steadfastness of Global GDP Becomes Increasingly Unpredictable Given the Many Direct and Indirect Economic Repercussions: World Economic Growth Projections (Real Gross Domestic Product (GDP), Annual % Change) for the Years 2022 Through 2025
    • EXHIBIT 3: All Eyes on Global Inflation, the Main Risk Factor in Global Markets: Global Headline Inflation Rates (In %) for the Years 2019 through 2025
    • EXHIBIT 4: With Oil Prices Influencing the Rate of inflation, it Remains the Most Watched Commodity in Global Markets: Global Average Annual Brent Crude Oil Price (In US$ Per Barrel) for Years 2019 through 2025
    • Global Market Outlook and Prospects
    • Rheumatoid Arthritis Diagnostic Tests Market in Sprint Mode with Government Support & Spending
    • The US and Europe Dominate the Global Market, Developing Countries to Witness Fastest Growth
    • Anti-Cyclic Citrullinated Peptide (anti-CCP) Tests Projected to Grow Significantly During the Forecast Period
    • Precision Diagnostics & Personalized Medicine as Major Trends
    • Concerns over Low Specificity & Sensitivity to Hinder Growth
    • Recent Market Activity
    • Influencer/Product/Technology Insights
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Rheumatoid Arthritis Propels the Demand for Rheumatoid Arthritis Diagnosis
    • EXHIBIT 5: Global Cost of Chronic Diseases (In US$ Billion) for the Years 2018 and 2030
    • Growing Aging Population to Drive the Demand for RA Diagnostic Tests
    • EXHIBIT 6: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Increasing Use of Rapid Diagnosis Tests Platform
    • Select List of RA Biomarkers used in Clinical Practice
    • Investigational Biomarkers to Diagnose and Monitor RA
    • New Biomarker Tests to Drive the Market Growth
    • Growing Demand for Multiple Tests
    • Repercussions of Sub Optimal Accuracy in RA Testing Drive the Need for Multiple Tests
    • Uptrend in Healthcare Expenditure Drives Opportunities
    • EXHIBIT 7: World Healthcare Expenditure (In US$ Billion) for the Years 2017-2023
    • Increase in Number of Hospitals & Diagnostics Centers Augurs Well for Market in Developing Regions
    • Increasing Obesity Levels Underpins Market Growth
    • EXHIBIT 8: Obesity Prevalence Rate (%) in Select Countries for the Years 2019 and 2030P
    • Burgeoning Patient Data Accentuates Worth of AI for Rheumatoid Arthritis Diagnosis
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Rheumatoid Arthritis Diagnosis Tests Market Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Serology Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Serology Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Serology Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Monitoring RA Treatment Efficiency Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Monitoring RA Treatment Efficiency Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Monitoring RA Treatment Efficiency Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ambulatory Surgical Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ambulatory Surgical Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Ambulatory Surgical Centers End-Use by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • Market Analytics
    • TABLE 20: USA Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • JAPAN
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • CHINA
    • TABLE 38: China Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: China 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: China 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • EUROPE
    • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • Market Analytics
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • FRANCE
    • TABLE 53: France Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: France 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: France 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • GERMANY
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • TABLE 71: UK Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Rheumatoid Arthritis Diagnosis Tests Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • Market Analytics
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • INDIA
    • TABLE 110: India Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: India 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: India 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030
  • AFRICA
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Rheumatoid Arthritis Diagnosis Tests by Test Type - Serology Tests and Monitoring RA Treatment Efficiency Tests Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by Test Type - Percentage Breakdown of Value Revenues for Serology Tests and Monitoring RA Treatment Efficiency Tests for the Years 2014, 2024 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Rheumatoid Arthritis Diagnosis Tests by End-Use - Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Rheumatoid Arthritis Diagnosis Tests by End-Use - Percentage Breakdown of Value Revenues for Diagnostic Laboratories End-Use, Hospitals End-Use and Ambulatory Surgical Centers End-Use for the Years 2014, 2024 & 2030

IV. COMPETITION